Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors

Add time:08/25/2019    Source:sciencedirect.com

Inhibition of MAO-B has been an effective strategy for the treatment of Parkinson’s disease. To find more potent and selective MAO-B inhibitors with novel chemical scaffold, we designed and synthesized a series of new 2,3-dihydro-1H-inden-1-amine derivatives on basis of our previous study. Furthermore, the corresponding structure-activity relationship (SAR) of these compounds is detailedly discussed. Compounds L4 (IC50 = 0.11 μM), L8 (IC50 = 0.18 μM), L16 (IC50 = 0.27 μM) and L17 (IC50 = 0.48 μM) showed similar MAO-B inhibitory activity as Selegiline. Moreover, L4, L16 and L17 also exhibited comparable selectivity with Selegiline, indicating that L4, L16 and L17 could be promising selective MAO-B inhibitors for further study.

We also recommend Trading Suppliers and Manufacturers of 5(1H)-Indolizinethione, 2,3-dihydro- (cas 113885-14-6). Pls Click Website Link as below: cas 113885-14-6 suppliers

Prev:A novel catalyst-free, eco-friendly, on water protocol for the synthesis of 2,3-dihydro-1H-perimidines
Next:Synthesis and characterization of a new class of unsymmetrical squaraines with 2,3-dihydro-1H-perimidine terminal groups)